Advanced in Polymorphous Low Grade Adenocarcinoma

Dr. Gerald S. Falchook

Oncology
Healthone Clinic Services - Oncology Hematology LLC
1800 Williams St, 300 Sarah Cannon Research, 
Denver, CO 
Clinical Trials:Currently Recruiting for 3 Trials
Offers Telehealth
Advanced in Polymorphous Low Grade Adenocarcinoma
Healthone Clinic Services - Oncology Hematology LLC
1800 Williams St, 300 Sarah Cannon Research, 
Denver, CO 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Gerald Falchook is an Oncologist in Denver, Colorado. Dr. Falchook is rated as an Advanced provider by MediFind in the treatment of Polymorphous Low Grade Adenocarcinoma. His top areas of expertise are Colorectal Cancer, Melanoma, Glioma, and Astrocytoma.

His clinical research consists of co-authoring 197 peer reviewed articles and participating in 32 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Licenses
Internal Medicine in TX
Hospital Affiliations
Hca Healthone Presbyterian St Lukes
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Denver Health Medical Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
SelectHealth
  • HMO
  • POS
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 5 Less Insurance Carriers -

Locations

HEALTHONE CLINIC SERVICES - ONCOLOGY HEMATOLOGY LLC
1800 Williams St, 300 Sarah Cannon Research, Denver, CO 80218

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

32 Clinical Trials

A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients With Advanced or Metastatic Solid Tumors
A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients With Advanced or Metastatic Solid Tumors
Enrollment Status: Recruiting
Publish Date: October 14, 2025
Intervention Type: Drug
Study Drugs: ART0380, Gemcitabine
Study Phase: Phase 1/Phase 2
Phase I/II Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT8009 in Patients With Nectin-4 Expressing Advanced Malignancies
Phase I/II Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT8009 in Patients With Nectin-4 Expressing Advanced Malignancies
Enrollment Status: Recruiting
Publish Date: September 26, 2025
Intervention Type: Drug
Study Drugs: BT8009, Nivolumab
Study Phase: Phase 1/Phase 2
Long-Term Follow-Up (LTFU) of Participants Treated With ADP Adoptive Cell Therapies
Long-Term Follow-Up (LTFU) of Participants Treated With ADP Adoptive Cell Therapies
Enrollment Status: Recruiting
Publish Date: July 03, 2024
Intervention Type: Biological
Study Phase: Phase 1
A Phase 1/2 Dose Escalation and Dose Expansion Study of Mecbotamab Vedotin (BA3011) Alone and in Combination With Nivolumab in Adult and Adolescent Patients 12 Years and Older With Advanced Solid Tumors
A Phase 1/2 Dose Escalation and Dose Expansion Study of Mecbotamab Vedotin (BA3011) Alone and in Combination With Nivolumab in Adult and Adolescent Patients 12 Years and Older With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: September 23, 2025
Intervention Type: Biological
Study Drug: CAB-AXL-ADC
Study Phase: Phase 1/Phase 2
Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells, Alone or in Combination With Other Agents, in HLA-A2+ Participants With NY-ESO-1 and/or LAGE-1a Positive Solid Tumors (IGNYTE-ESO)
Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells, Alone or in Combination With Other Agents, in HLA-A2+ Participants With NY-ESO-1 and/or LAGE-1a Positive Solid Tumors (IGNYTE-ESO)
Enrollment Status: Active_not_recruiting
Publish Date: July 16, 2025
Intervention Type: Drug
Study Drugs: Letetresgene Autoleucel, Fludarabine, Cyclophosphamide
Study Phase: Phase 2
An Open-label, Dose Escalation, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-676 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced or Metastatic Solid Tumors
An Open-label, Dose Escalation, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-676 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced or Metastatic Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: June 13, 2025
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 1/2 Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001)
A Phase 1/2 Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001)
Enrollment Status: Active_not_recruiting
Publish Date: June 04, 2025
Intervention Type: Drug
Study Drug: Selpercatinib
Study Phase: Phase 1/Phase 2
A Phase I, Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Subjects With Solid Tumors and Non-Hodgkin's Lymphoma
A Phase I, Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Subjects With Solid Tumors and Non-Hodgkin's Lymphoma
Enrollment Status: Completed
Publish Date: March 10, 2025
Intervention Type: Drug
Study Drugs: GSK3326595, Pembrolizumab
Study Phase: Phase 1
A Phase 1a/b Non-randomized, Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Sterile BPM31510 (Ubidecarenone, USP) Nanosuspension Injection Administered Intravenously to Patients With Solid Tumors
A Phase 1a/b Non-randomized, Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Sterile BPM31510 (Ubidecarenone, USP) Nanosuspension Injection Administered Intravenously to Patients With Solid Tumors
Enrollment Status: Completed
Publish Date: February 19, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1/2 Safety and Efficacy Dose Escalation / Dose Expansion Study of a CAB-ROR2-ADC, Alone and in Combination With a PD-1 Inhibitor, in Patients With Advanced Solid Tumors (Ph1) and Melanoma and NSCLC Patients (Ph2)
A Phase 1/2 Safety and Efficacy Dose Escalation / Dose Expansion Study of a CAB-ROR2-ADC, Alone and in Combination With a PD-1 Inhibitor, in Patients With Advanced Solid Tumors (Ph1) and Melanoma and NSCLC Patients (Ph2)
Enrollment Status: Completed
Publish Date: January 15, 2025
Intervention Type: Biological
Study Drug: CAB-ROR2-ADC
Study Phase: Phase 1/Phase 2
A Phase 1, Multi-Center, Dose Escalation, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-3068 in Adult Patients With Advanced Solid Tumors
A Phase 1, Multi-Center, Dose Escalation, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-3068 in Adult Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: December 16, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1/1B First-in-Human Study of the SHP2 Inhibitor BBP-398 (Formerly Known as IACS-15509) in Patients With Advanced Solid Tumors
A Phase 1/1B First-in-Human Study of the SHP2 Inhibitor BBP-398 (Formerly Known as IACS-15509) in Patients With Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: December 12, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1, Open-Label Dose Escalation First-in-Human Study to Evaluate the Tolerability, Safety, Maximum Tolerated Dose, Preliminary Clinical Activity and Pharmacokinetics of AM0010 in Patients With Advanced Solid Tumors
A Phase 1, Open-Label Dose Escalation First-in-Human Study to Evaluate the Tolerability, Safety, Maximum Tolerated Dose, Preliminary Clinical Activity and Pharmacokinetics of AM0010 in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: November 15, 2024
Intervention Type: Drug
Study Phase: Phase 1
Phase 1/2 Open Label Dose-escalation and Expansion Trial of NKT2152 an Orally Administered HIF2α Inhibitor to Investigate Safety Pharmacokinetics Pharmacodynamics and Clinical Activity in Patients with Advanced Clear Cell Renal Cell Carcinoma
Phase 1/2 Open Label Dose-escalation and Expansion Trial of NKT2152 an Orally Administered HIF2α Inhibitor to Investigate Safety Pharmacokinetics Pharmacodynamics and Clinical Activity in Patients with Advanced Clear Cell Renal Cell Carcinoma
Enrollment Status: Active_not_recruiting
Publish Date: October 16, 2024
Intervention Type: Drug
Study Drug: Oral NKT2152
Study Phase: Phase 1/Phase 2
A Phase 1, Open-Label, Dose-Escalation, Dose-Finding Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subjects With Advanced Solid Tumors
A Phase 1, Open-Label, Dose-Escalation, Dose-Finding Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subjects With Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: August 09, 2024
Intervention Type: Drug
Study Phase: Phase 1
An Open-Label, Randomized-Sequence, Multicenter, Single-Crossover Study to Assess the Relative Bioavailability and Bioequivalence of Niraparib Tablet Formulation Compared to Niraparib Capsule Formulation in Patients With Advanced Solid Tumors
An Open-Label, Randomized-Sequence, Multicenter, Single-Crossover Study to Assess the Relative Bioavailability and Bioequivalence of Niraparib Tablet Formulation Compared to Niraparib Capsule Formulation in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: July 25, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Multicenter, Open-label, Phase 2 Study of Imprime PGG and Pembrolizumab in Subjects With Advanced Melanoma Failing Front-line Treatment With Checkpoint Inhibitors (CPI) or TNBC Failing Front-line Chemotherapy for Metastatic Disease
A Multicenter, Open-label, Phase 2 Study of Imprime PGG and Pembrolizumab in Subjects With Advanced Melanoma Failing Front-line Treatment With Checkpoint Inhibitors (CPI) or TNBC Failing Front-line Chemotherapy for Metastatic Disease
Enrollment Status: Completed
Publish Date: July 09, 2024
Intervention Type: Biological, Drug
Study Drugs: Imprime PGG, Pembrolizumab
Study Phase: Phase 2
A Phase 1/2 Study of TPX-0046, A Novel Oral RET/SRC Inhibitor in Adult Subjects With Advanced/Metastatic Solid Tumors Harboring Oncogenic RET Fusions or Mutations
A Phase 1/2 Study of TPX-0046, A Novel Oral RET/SRC Inhibitor in Adult Subjects With Advanced/Metastatic Solid Tumors Harboring Oncogenic RET Fusions or Mutations
Enrollment Status: Terminated
Publish Date: June 13, 2024
Intervention Type: Drug
Study Drug: TPX-0046
Study Phase: Phase 1/Phase 2
A Phase 1 Multicenter Global First in Human Study of the CD73 Inhibitor LY3475070 as Monotherapy or in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
A Phase 1 Multicenter Global First in Human Study of the CD73 Inhibitor LY3475070 as Monotherapy or in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
Enrollment Status: Completed
Publish Date: April 05, 2024
Intervention Type: Drug
Study Drugs: LY3475070, Pembrolizumab
Study Phase: Phase 1
A Phase 1b/2 Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Advanced Solid Tumors (TRIDENT-2)
A Phase 1b/2 Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Advanced Solid Tumors (TRIDENT-2)
Enrollment Status: Terminated
Publish Date: April 02, 2024
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 1b/2a Pilot Study to Evaluate the Safety and Tolerability of Autologous T-Cells Expressing Enhanced TCRs (T Cell Receptors) Specific for NY-ESO-1/LAGE-1a (GSK3377794) Alone, or in Combination With Pembrolizumab in HLA-A2+ Participants With NY-ESO-1- or LAGE-1a-Positive Advanced or Recurrent Non-Small Cell Lung Cancer
A Phase 1b/2a Pilot Study to Evaluate the Safety and Tolerability of Autologous T-Cells Expressing Enhanced TCRs (T Cell Receptors) Specific for NY-ESO-1/LAGE-1a (GSK3377794) Alone, or in Combination With Pembrolizumab in HLA-A2+ Participants With NY-ESO-1- or LAGE-1a-Positive Advanced or Recurrent Non-Small Cell Lung Cancer
Enrollment Status: Terminated
Publish Date: February 23, 2024
Intervention Type: Drug
Study Drugs: Letetresgene autoleucel, Pembrolizumab
Study Phase: Phase 1/Phase 2
A Phase 1 Open-label Study of SNX281 Given as Monotherapy and in Combination With a Checkpoint Inhibitor in Subjects With Advanced Solid Tumors and Lymphoma
A Phase 1 Open-label Study of SNX281 Given as Monotherapy and in Combination With a Checkpoint Inhibitor in Subjects With Advanced Solid Tumors and Lymphoma
Enrollment Status: Terminated
Publish Date: January 30, 2024
Intervention Type: Drug
Study Drugs: SNX281, Pembrolizumab
Study Phase: Phase 1
A Phase 1a/1b Trial Investigating the CSF-1R Inhibitor LY3022855 in Combination With Durvalumab (MEDI4736) or Tremelimumab in Patients With Advanced Solid Tumors
A Phase 1a/1b Trial Investigating the CSF-1R Inhibitor LY3022855 in Combination With Durvalumab (MEDI4736) or Tremelimumab in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: October 16, 2023
Intervention Type: Drug
Study Phase: Phase 1
Effects of Multiple Doses of Abemaciclib on the Pharmacokinetics of Cytochrome P450 (CYP) 1A2, CYP2C9, CYP2D6, and CYP3A Substrates (Caffeine, Warfarin, Dextromethorphan, and Midazolam) in Cancer Patients
Effects of Multiple Doses of Abemaciclib on the Pharmacokinetics of Cytochrome P450 (CYP) 1A2, CYP2C9, CYP2D6, and CYP3A Substrates (Caffeine, Warfarin, Dextromethorphan, and Midazolam) in Cancer Patients
Enrollment Status: Completed
Publish Date: October 18, 2022
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Enrollment Status: Terminated
Publish Date: April 28, 2022
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 1/2a, Dose-escalation Study of FF-10502-01 for the Treatment of Advanced Solid Tumors and Lymphomas
A Phase 1/2a, Dose-escalation Study of FF-10502-01 for the Treatment of Advanced Solid Tumors and Lymphomas
Enrollment Status: Completed
Publish Date: April 13, 2022
Intervention Type: Drug
Study Drug: FF-10502-01
Study Phase: Phase 1/Phase 2
A Phase 1 Open-label Dose Escalation Study of CGX1321 in Subjects With Advanced Solid Tumors With Expansion in Advanced Gastrointestinal Tumors and Phase 1b Study of CGX1321 in Combination With Pembrolizumab in Subjects With Advanced Colorectal Cancer or in Combination With Encorafenib + Cetuximab in Subjects With BRAFV600E Mutated Advanced Colorectal Cancer
A Phase 1 Open-label Dose Escalation Study of CGX1321 in Subjects With Advanced Solid Tumors With Expansion in Advanced Gastrointestinal Tumors and Phase 1b Study of CGX1321 in Combination With Pembrolizumab in Subjects With Advanced Colorectal Cancer or in Combination With Encorafenib + Cetuximab in Subjects With BRAFV600E Mutated Advanced Colorectal Cancer
Enrollment Status: Unknown
Publish Date: January 26, 2022
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1, Two-Cohort, Open-Label, Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With Locally Recurrent or Metastatic ER+ Breast Cancer
A Phase 1, Two-Cohort, Open-Label, Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With Locally Recurrent or Metastatic ER+ Breast Cancer
Enrollment Status: Completed
Publish Date: December 15, 2021
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1, First-in-Human, Safety, Dose Tolerance, Pharmacokinetics, and Pharmacodynamics Study of CPX-POM in Patients With Advanced Solid Tumors.
A Phase 1, First-in-Human, Safety, Dose Tolerance, Pharmacokinetics, and Pharmacodynamics Study of CPX-POM in Patients With Advanced Solid Tumors.
Enrollment Status: Completed
Publish Date: December 03, 2021
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1-2 Dose Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Advanced Solid Tumors
A Phase 1-2 Dose Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: November 02, 2020
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors
An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: October 19, 2020
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 2, Open-Label, Randomized, Non-Comparative Study With Preliminary Dose Finding to Evaluate eFT508 Monotherapy or eFT508 in Combination With Avelumab in Subjects With Microsatellite Stable Relapsed or Refractory Colorectal Cancer
A Phase 2, Open-Label, Randomized, Non-Comparative Study With Preliminary Dose Finding to Evaluate eFT508 Monotherapy or eFT508 in Combination With Avelumab in Subjects With Microsatellite Stable Relapsed or Refractory Colorectal Cancer
Enrollment Status: Completed
Publish Date: July 18, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 29 Less Clinical Trials

194 Total Publications

A phase I, open-label, multicentre, first-in-human study to evaluate safety, pharmacokinetics and efficacy of AMG 404, a PD-1 inhibitor, in patients with advanced solid tumours.
A phase I, open-label, multicentre, first-in-human study to evaluate safety, pharmacokinetics and efficacy of AMG 404, a PD-1 inhibitor, in patients with advanced solid tumours.
Journal: BMJ open
Published: May 02, 2025
Similar Doctors
Distinguished in Polymorphous Low Grade Adenocarcinoma
Dr. Daniel Bowles
Oncology | Hematology Oncology | Hematology
Distinguished in Polymorphous Low Grade Adenocarcinoma
Dr. Daniel Bowles
Oncology | Hematology Oncology | Hematology

University Physicians Incorporated

13123 E 16th Ave, 
Aurora, CO 
 (6.9 miles away)
720-777-1234
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Daniel Bowles is an Oncologist and a Hematologist Oncology provider in Aurora, Colorado. Dr. Bowles is rated as a Distinguished provider by MediFind in the treatment of Polymorphous Low Grade Adenocarcinoma. His top areas of expertise are Thyroid Cancer, Anaplastic Thyroid Cancer, Adenoid Cystic Carcinoma, Salivary Gland Tumors, and Lymphadenectomy.

Distinguished in Polymorphous Low Grade Adenocarcinoma
Dr. Ammar W. Sukari
Oncology | Hematology
Distinguished in Polymorphous Low Grade Adenocarcinoma
Dr. Ammar W. Sukari
Oncology | Hematology

Platte Valley Medical Group LLC

1606 Prairie Ctr Pkwy, 
Brighton, CO 
 (18.4 miles away)
Languages Spoken:
English, Arabic
See accepted insurances
Accepting New Patients

Ammar Sukari is an Oncologist and a Hematologist in Brighton, Colorado. Dr. Sukari is rated as a Distinguished provider by MediFind in the treatment of Polymorphous Low Grade Adenocarcinoma. His top areas of expertise are Head and Neck Squamous Cell Carcinoma (HNSCC), Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Laryngeal Cancer, and Gastrostomy. Dr. Sukari is currently accepting new patients.

Advanced in Polymorphous Low Grade Adenocarcinoma
Dr. Jessica Mcdermott
Oncology
Advanced in Polymorphous Low Grade Adenocarcinoma
Dr. Jessica Mcdermott
Oncology

University Physicians Incorporated

13123 E 16th Ave, 
Aurora, CO 
 (6.9 miles away)
720-777-1234
Experience:
16+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jessica Mcdermott is an Oncologist in Aurora, Colorado. Dr. Mcdermott has been practicing medicine for over 16 years and is rated as a Distinguished provider by MediFind in the treatment of Polymorphous Low Grade Adenocarcinoma. Her top areas of expertise are Oral Squamous Cell Carcinoma, Adenoid Cystic Carcinoma, Squamous Cell Skin Carcinoma, and Salivary Gland Tumors.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Falchook's expertise for a condition
ConditionClose
    View All 41 Advanced Conditions
    View All 63 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile